Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 11 | 2022 | 126 | 2.940 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 11 | 2023 | 843 | 2.430 |
Why?
|
| Immunotherapy, Adoptive | 9 | 2022 | 145 | 2.330 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2021 | 32 | 1.710 |
Why?
|
| Lymphoma, B-Cell | 5 | 2022 | 101 | 1.390 |
Why?
|
| Antigens, CD19 | 7 | 2022 | 36 | 1.280 |
Why?
|
| Transplantation, Autologous | 6 | 2021 | 321 | 1.140 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2021 | 254 | 0.860 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 109 | 0.830 |
Why?
|
| Jehovah's Witnesses | 1 | 2021 | 18 | 0.830 |
Why?
|
| Blood Component Removal | 1 | 2020 | 27 | 0.820 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 177 | 0.810 |
Why?
|
| Transplantation Conditioning | 3 | 2021 | 371 | 0.770 |
Why?
|
| Lymphoma | 2 | 2018 | 258 | 0.730 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 2346 | 0.590 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2016 | 77 | 0.590 |
Why?
|
| Biological Products | 3 | 2022 | 133 | 0.580 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2022 | 373 | 0.580 |
Why?
|
| Lymphoma, Follicular | 3 | 2022 | 68 | 0.570 |
Why?
|
| Graft vs Host Disease | 3 | 2023 | 351 | 0.530 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 38 | 0.520 |
Why?
|
| Hepatitis B | 1 | 2014 | 70 | 0.500 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 723 | 0.470 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1328 | 0.440 |
Why?
|
| Humans | 32 | 2023 | 80897 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2023 | 1219 | 0.310 |
Why?
|
| Sarcopenia | 2 | 2016 | 12 | 0.300 |
Why?
|
| T-Lymphocytes | 4 | 2021 | 1190 | 0.300 |
Why?
|
| Retrospective Studies | 5 | 2022 | 7560 | 0.300 |
Why?
|
| Aged | 12 | 2022 | 17475 | 0.270 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2021 | 44 | 0.260 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 2274 | 0.250 |
Why?
|
| Veterans | 4 | 2016 | 59 | 0.240 |
Why?
|
| Rituximab | 4 | 2016 | 103 | 0.230 |
Why?
|
| Middle Aged | 11 | 2022 | 23961 | 0.220 |
Why?
|
| Hodgkin Disease | 1 | 2023 | 172 | 0.220 |
Why?
|
| Geriatric Assessment | 2 | 2020 | 159 | 0.220 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 171 | 0.210 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 101 | 0.210 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 131 | 0.210 |
Why?
|
| Prognosis | 2 | 2018 | 3544 | 0.200 |
Why?
|
| Cladribine | 1 | 2019 | 35 | 0.190 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 39 | 0.190 |
Why?
|
| Survival Analysis | 2 | 2021 | 1512 | 0.190 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 313 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 181 | 0.180 |
Why?
|
| Adult | 7 | 2022 | 24636 | 0.180 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 124 | 0.180 |
Why?
|
| United States | 6 | 2022 | 6169 | 0.180 |
Why?
|
| Patient Selection | 2 | 2019 | 661 | 0.180 |
Why?
|
| Male | 12 | 2022 | 39412 | 0.170 |
Why?
|
| Disease Management | 1 | 2019 | 317 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2019 | 382 | 0.160 |
Why?
|
| Patient Care Team | 1 | 2019 | 268 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 78 | 0.160 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 296 | 0.160 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 261 | 0.160 |
Why?
|
| Cyclophosphamide | 4 | 2021 | 288 | 0.150 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 7 | 0.150 |
Why?
|
| Female | 11 | 2022 | 42456 | 0.150 |
Why?
|
| Body Composition | 1 | 2016 | 63 | 0.150 |
Why?
|
| Up-Regulation | 1 | 2018 | 692 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 267 | 0.140 |
Why?
|
| Stem Cell Transplantation | 3 | 2021 | 176 | 0.140 |
Why?
|
| Anthracyclines | 1 | 2015 | 34 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 302 | 0.130 |
Why?
|
| Doxorubicin | 4 | 2016 | 280 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 286 | 0.130 |
Why?
|
| Survivors | 1 | 2016 | 209 | 0.130 |
Why?
|
| Febrile Neutropenia | 1 | 2014 | 14 | 0.130 |
Why?
|
| Pandemics | 1 | 2020 | 628 | 0.130 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 121 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 696 | 0.130 |
Why?
|
| Transplantation, Homologous | 3 | 2020 | 978 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1163 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1142 | 0.120 |
Why?
|
| Time Factors | 1 | 2021 | 5094 | 0.110 |
Why?
|
| Vincristine | 3 | 2016 | 107 | 0.110 |
Why?
|
| Prednisone | 3 | 2016 | 252 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2014 | 743 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2014 | 488 | 0.100 |
Why?
|
| Recurrence | 2 | 2023 | 1118 | 0.090 |
Why?
|
| Adolescent | 1 | 2021 | 8669 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2021 | 795 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1363 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2023 | 3926 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6214 | 0.060 |
Why?
|
| Melphalan | 1 | 2023 | 95 | 0.060 |
Why?
|
| Thiotepa | 1 | 2021 | 32 | 0.050 |
Why?
|
| Histiocytes | 1 | 2021 | 22 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 223 | 0.050 |
Why?
|
| Incidence | 2 | 2016 | 1540 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2019 | 7492 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2021 | 144 | 0.050 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 24 | 0.050 |
Why?
|
| Chimerism | 1 | 2020 | 36 | 0.050 |
Why?
|
| Filgrastim | 1 | 2019 | 56 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 48 | 0.050 |
Why?
|
| Hydrazines | 1 | 2019 | 29 | 0.050 |
Why?
|
| Health Care Rationing | 1 | 2020 | 77 | 0.050 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 55 | 0.050 |
Why?
|
| Standard of Care | 1 | 2019 | 86 | 0.050 |
Why?
|
| Triazoles | 1 | 2019 | 96 | 0.050 |
Why?
|
| Cytarabine | 1 | 2019 | 211 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 561 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 437 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 705 | 0.040 |
Why?
|
| Palliative Care | 1 | 2019 | 234 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 243 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2020 | 419 | 0.040 |
Why?
|
| Steroids | 1 | 2018 | 165 | 0.040 |
Why?
|
| Abdominal Fat | 1 | 2016 | 13 | 0.040 |
Why?
|
| Subcutaneous Fat | 1 | 2016 | 16 | 0.040 |
Why?
|
| Neutropenia | 1 | 2016 | 211 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 2583 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 108 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 901 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 824 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 426 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 948 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 3052 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1013 | 0.030 |
Why?
|
| Animals | 2 | 2023 | 25628 | 0.030 |
Why?
|
| Hospitalization | 1 | 2016 | 768 | 0.030 |
Why?
|
| Mutation | 1 | 2022 | 3792 | 0.030 |
Why?
|
| Mice | 1 | 2023 | 10809 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 5725 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2440 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3114 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 5137 | 0.020 |
Why?
|